Vision: Vol. 3, Antithrombotic therapy for surgical bioprosthetic valves and valve repair

Vision, 3rd episode: antithrombotic Tx. in bioprosthetic valves and valve repair

Umbrella: Heart Failure, Panel 4, Heart Failure with EF more than 40%

Umbrella: HF, Heart Failure with EF>40%

Umbrella: Heart Failure, Panel 3, Acute Decompensated Heart Failure

Umbrella: HF, Acute Decompensated HF

Umbrella: Heart Failure, Panel 2, Non-pharmacologic Approach to HF Management

Umbrella: HF, Non-pharmacologic Approach to HF

Umbrella: Heart Failure, Panel 1, Pharmacotherapy in HFrEF

Umbrella: HF, Pharmacotherapy in HFrEF

ESC 2022 congress coverage: INVICTUS trial

ESC 2022: INVICTUS trial

ESC 2022 congress coverage: DELIVER trial

ESC 2022: DELIVER trial

ESC 2022 congress coverage: ALL-HEART trial

ESC 2022: ALL-HEART trial

ESC 2022 congress coverage: REVIVED trial

ESC 2022: REVIVED trial

ESC 2022 congress coverage: DANCAVAS trial

ESC 2022: DANCAVAS trial

ESC 2022 congress coverage: DANFLU-1 trial

ESC 2022: DANFLU-1 trial

ESC 2022 congress coverage: ADVOR trial

ESC 2022: ADVOR trial

ESC 2022 congress coverage: PERSPECTIVE trial

ESC 2022: PERSPECTIVE trial

ESC 2022 congress coverage: SECURE trial

ESC 2022: SECURE trial

ESC 2022 congress coverage: TIME trial

ESC 2022: TIME trial

A preview of ESC congress 2022

A preview of ESC congress 2022

Pulse Wave Velocity, a marker for arterial stiffness and a risk modifier for ASCVD

PWV in a nutshell

Hypertension and Hyperlipidemia Academy No. 10

H&H Academy No. 10

Antiplatelet Journal Scan

An Update on Antiplatelet Therapy

Vision: Vol. 2, Distal DVTs

The Second episode of Vision: distal DVTs

Hypertension and Hyperlipidemia Academy, 10: for non-physician healthcare profesionals

H&H Academy 10, for non-physician healthcare professionals

Vision: Vol. 1, What is Lp(a)?

The first episode of Vision: Lp(a)

Hypertension and Hyperlipidemia Academy, 9th session

9th session of H&H Academy

Daily Cardiology Symposium 1401, Day 2 Panel 4: Valvular heart disease

DCS 1401: Valvular heart disease

Daily Cardiology Symposium 1401, Day 2 Panel 3: Heart Failure

DCS 1401: Heart Failure

Daily Cardiology Symposium 1401, Day 2 Panel 2: Device therapy in cardiovascular diseases

Daily Cardiology Symposium 1401, Day 2 Panel 1: Arrhythmia

DCS 1401: Arrhythmia

Young Cardiologist Award final review Panel

Young Cardiologist Award Panel

Daily Cardiology Symposium 1401, Day 1 Panel 4: Peripheral vascular diseases

DCS 1401: Peripheral vascular diseases

Daily Cardiology Symposium 1401, Day 1 Panel 3: Venous thromboembolism (VTE) prophylaxis

DCS 1401: Venous thromboembolism (VTE) prophylaxis

Daily Cardiology Symposium 1401, Day 1 Panel 2: Revascularization in CAD

DCS 1401: Revascularization in CAD

Daily Cardiology Symposium 1401, Day 1 Panel 1: Pharmacotherapy in CAD

DCS 1401: Pharmacotherapy in CAD

Daily Cardiology Symposium 1401, opening remarks

DCS 1401: opening remarks

Hypertension and Hyperlipidemia Academy, 8th session

8th session of H&H Academy

Hypertension and Hyperlipidemia Academy, 7th session

7th session of H&H Academy

Cardiometabolic grand round: session 6

The 6th cardiometabolic grand round

Umbrella: Hypertension, hypertension and pregnancy

Umbrella: HTN, HTN and pregnancy

Umbrella: Hypertension, secondary hypertension

Umbrella: HTN, secondary HTN

Umbrella: Hypertension, Acute severe hypertension

Umbrella: HTN, acute severe HTN

Umbrella: Hypertension, Challenges in the diagnosis & management of HTN

Umbrella: HTN, diagnosis and management of HTN

Hypertension and Hyperlipidemia Academy, 6th session

6th session of H&H Academy

which prophylaxis? for whom? VTE prophylaxis panel discussion

Case-based panel discussion on VTE prophylaxis

Hypertension and Hyperlipidemia Academy: for nurses and medical assistants

H&H Academy: nurses and assistants

Hypertension and Hyperlipidemia Academy 5, a hybrid event

5th session of H&H Academy, online and onsite

Umbrella Heart and Stroke: session 4, Antithrombotic therapy for the secondary prevention of stroke

Umbrella H&S: session 4, secondary prevention of stroke

Umbrella Heart and Stroke: session 3, Atrial fibrillation screening

Umbrella H&S: session 3, AF screening

Umbrella Heart and Stroke: session 2, carotid stenosis and stroke

Umbrella H&S: session 2, carotid stenosis

Umbrella Heart and Stroke: session 1, detecting & managing patients with PFO

Umbrella H&S: session1, PFO

Hypertension and Hyperlipidemia Academy: 4th session

H&H Academy session 4

An introduction to a new series; HeartCast

HeartCast introduction

Ticagrelor Hub: when to use and which dose?

The dosage and indications of Ticagrelor

Cardiometabolic Grand round, Session 5

The 5th session of Cardiometabolic grand round

Primary prevention in dyslipidemia as the only cardiovascular risk factor

Dyslipidemia in primary prevention of low-risk patients

Late-breaking Science in Cardiovascular disease prevention

ESC 2021 cardiovascular prevention guideline lectures and discussion

Management of dyslipidemia in diabetic patients

DLP and T2DM: approach and management

DiaBeat: The Beating Heart of Diabetes (8th session)

8th Diabetes Masterclass for Cardiologists

The clinical landscape for Diabetes and Cardiovascular disease

T2DM and cardiovascular diseases: The clinical landscape

DiaBeat: The Beating Heart of Diabetes (7th session), a scientific debate

7th Diabetes Masterclass for Cardiologists

From optimal medical therapy to revascularization in CCS

Choosing the best therapeutic strategy in CCS

Antithrombotic lighthouse, Cases and Faces: antithrombotic therapy in CAD

Antithrombotic regimens in CAD

Symptom matters: angina control in coronary artery disease

From surrogates to symptom control in CAD

Tailored Antithrombotic therapy for CCS patients

Best individual antithrombotic strategy in CCS

Marking the antiplatelet therapy maze in ACS

How to prevent atherosclerotic cardiovascular events

DiaBeat: The Beating Heart of Diabetes (6th session)

6th Diabetes Masterclass for Cardiologists

Cardiometabolic Grand Round: 4th session

Guideline-directed cardiovascular evaluations before surgery

Cardiovascular complications of T2DM: the preventive role of SGLT2Is

SGLT2Is and the prevention of cardiovascular complications in T2DM

DCS 1400: session 8, Valvular Heart disease

The eighth panel of DCS 1400: Valvular Heart disease

DCS 1400: session 7, VTE

The seventh panel of DCS 1400: Venous Thromboembolism

DCS 1400: session 6, Arrhythmia

The sixth panel of DCS 1400: Arrhythmia

DCS 1400: session 5, HF

The fifth panel of DCS 1400: Heart Failure

DCS 1400: session 4, ACS

The fourth panel of DCS 1400: Acute coronary syndrome

DCS 1400: session 3, CCS

The third panel of DCS 1400: Chronic coronary syndrome

DCS 1400: session 2, Diabetes for cardiologists

The second panel of DCS 1400: diabetes for cardiologists

DCS 1400: session 1, HTN and DLP

The first panel of DCS 1400: hypertension and dyslipidemia

DCS 1400: welcome remarks

The initial greetings of DCS 1400

How to reduce the atherosclerotic cardiovascular risk

A case-based Review on HTN and DLP management

The evolution of antiplatelet therapy in CAD: a 45 year journey

A brief history of anti-platelet therapy in CAD

Dual antiplatelet therapy in2021: Current recommendations

The latest updates on DAPT

DiaBeat: The Beating Heart of Diabetes (5th session)

5th Diabetes Masterclass for Cardiologists

DiaBeat: The Beating Heart of Diabetes (4th session)

4th Diabetes Masterclass for Cardiologists

DiaBeat: The Beating Heart of Diabetes (3rd session)

3rd Diabetes Masterclass for Cardiologists

DiaBeat: The Beating Heart of Diabetes (2nd session)

2nd Diabetes Masterclass for Cardiologists

DiaBeat: The Beating Heart of Diabetes (1st session)

1st Diabetes Masterclass for Cardiologists

PCSK9 inhibitors place in patients with cardiometabolic diseases

PCSK9 inhibitors from two perspectives of Endocrinologist & Cardiologist

Cardiometabolic Grand Round (3)

A brief talk on DM medication challenges in patients with CVD

Introduction: Evolution of DOACs and their place in Guidelines

A brief report of Guidelines mentioned DOACs place in practice

10th Case: Drug Drug Interactions

DOACs important interactions in clinical practice

To DOAC or Not to DOAC

Rapid review of oral anticoagulation practice in different clinical scenarios

9th Case: Renal Insufficiency

OAC Management in Patients with CKD

8th Case: Intracranial Bleed

OAC Choice in High Thrombotic Risk Patients after ICH

Seventh Case: Thrombocytopenia

Any Concerns for OACs Use in Patients with Thrombocytopenia

Sixth Case: Hepatic Impairment

OAC of choice in patients with hepatic impairment, any difference between DOACs?

Fifth Case: Stable ASCVD

Low dose Rivaroxaban in SIHD, COMPASS trial

Forth Case: Extreme Body Weights

OAC choice in patients with obesity or low body weights, any role for DOACs?

Third Case: AF & Artificial Heart Valves

OAC of choice in patients with artificial heart valves

Second Case: Cancer associated VTE

Anticoagulation of choice in patients with cancer, the importance of DDI

First Case: Elective PCI and AF

Antithrombotic regimen of choice in patients with AF undergoing elective PCI

Complete Session;SGLT2 inhibition: Making waves in the heart failure landscape

Role of SGLT2 inhibitors in HF patients from two perspectives: Endocrinology & Cardiology

SGLT2 inhibitors in the treatment of HF: the future is bright?

Cardiologist Perspective on SGLT2 inhibitors

SGLT2 inhibition: A snapshot into their evolution

Endocrinologist Perspective on SGLT2 inhibitors

SGLT2 inhibition: Making waves in the heart failure landscape

Role of SGLT2 inhibitors in HF patients from two perspectives: Endocrinology & Cardiology

Residents’ Island: Abidi CVD Prevention Academy

Multidisciplinary approach to CVD Prevention

Cardiometabolic Grand Round (2)

A brief talk on DM medication challenges in patients with CVD

Cardiometabolic Grand Round (1)

A brief talk on DM management in patients with CVD

How to Implement the Newest Diabetes Therapies in HF Treatment

New insight from EMPEROR Reduced Trial

Paradigm Shift in Treating Intermediate Risk Pulmonary Embolism

Concise Talk on Intermediate Risk Pulmonary Embolism, update by an expert in the field

What we learned from ESC Congress about HTN Management

A Brief Discussion on HTN Management Pearls of ESC 2020

VTE Prophylaxis in Patients with COVID-19

Challenges on VTE Prophylaxis in different settings (inpatient, outpatient, upon discharge)

ESC 2020 Congress Coverage What is new on NSTE-ACS Guideline: a panel discussion

Brief Discussion on the New ESC Guideline on NSTE-ACS

Diabetes and Cardiovascular Diseases

On the occasion of World Heart Day 2020 for the management of Cardiovascular risk factors

Smoking and the Heart the Struggle Continues

On the occasion of World Heart Day 2020 for the management of Cardiovascular risk factors

The weight of the world: The global challenge of obesity

On the occasion of World Heart Day 2020 for the management of Cardiovascular risk factors

Ground-breaking research from ESC Congress 2020 (23)

Part Twenty-three: Trial Review, ELDERCARE-AF

Ground-breaking research from ESC Congress 2020 (22)

Part Twenty-Two: Trial Review, ATPCI

Ground-breaking research from ESC Congress 2020 (21)

Part Twenty-One: Trial Review, BPLTTC (CANCER)

Ground-breaking research from ESC Congress 2020 (20)

Part Twenty: Trial Review, POPULAR TAVI

Ground-breaking research from ESC Congress 2020 (19)

Part Nineteen: Trial Review, EXPLORER-HCM

Ground-breaking research from ESC Congress 2020 (18)

Part Eighteen: Trial Review, HOME-PE

Ground-breaking research from ESC Congress 2020 (17)

Part Seventeen: Trial Review, REALITY

Ground-breaking research from ESC Congress 2020 (16)

Part Sixteen: Trial Review, BPLTTC

Ground-breaking research from ESC Congress 2020 (15)

Part Fifteen: Trial Review, PARALLAX

Ground-breaking research from ESC Congress 2020 (14)

Part Fourteen: Trial Review, POPULAR CABG

Ground-breaking research from ESC Congress 2020 (13)

Part Thirteen: Trial Review, BAMI

Ground-breaking research from ESC Congress 2020 (12)

Part Twelve: Trial Review, EVAPORATE

Ground-breaking research from ESC Congress 2020 (11)

Part Eleven: Trial Review, DAPA-CKD

Ground-breaking research from ESC Congress 2020 (10)

Part Ten: Trial Review, DECLARE-TIMI

Ground-breaking research from ESC Congress 2020 (9)

Part Nine: Trial Review, RATE-AF

Ground-breaking research from ESC Congress 2020 (8)

Part Eight: Trial Review, COPS

Ground-breaking research from ESC Congress 2020 (7)

Part Seven: Trial Review, COLCOT

Ground-breaking research from ESC Congress 2020 (6)

Part Six: Trial Review, LoDoCo2

Ground-breaking research from ESC Congress 2020 (5)

Part Five: Trial Review, EAST-AFNET4

Ground-breaking research from ESC Congress 2020 (4)

Part Four: Trial Review, BRACE-CORONA

Ground-breaking research from ESC Congress 2020 (3)

Part Three: Trial Review; THEMIS, PAD

Ground-breaking research from ESC Congress 2020 (2)

Part Two: Trial Review, EMPEROR-REDUCED

Ground-breaking research from ESC Congress 2020

Congress Coverage: Introduction

Ground-breaking research from ESC Congress 2020

Brief Review of Main Trials Discussed in ESC Congress 2020

Shielding the Brain From Stroke

A case based discussion on optimization of antithrombotic therapy in patients with ischemic stroke

Current Cardiology Practice of Antithrombotics in ASCVD: A Case Based Panel Discussion

Brief discussion on choice of antithrombotic agents in patients with chronic coronary syndrome and peripheral artery disease

Cardiometabolic Care Network

Interprofessional Collaboration Practice in Risk Management of ASCVD

Optimizing Heart Failure Care Throughout the Patient Journey

A Case Based Panel Comprehensive Discussion on HF Pharmacotherapy

Low-dose Rivaroxaban in Management of PAD Patients

Insights from COMPASS & VOYAGER Trials

Rivaroxaban on Board for Chronic ASCVD

How DPI Found Its Way into Clinical Practice

Low-dose Rivaroxaban in Management of Post-Revascularized CAD Patients

Insights from COMPASS-PCI & COMPASS-CABG Trials

COVID-19 and thrombotic or thromboembolic disease: implication for prevention, antithrombotic therapy, and follow up

Antithrombotic challenge in patients with COVID-19; focus on JACC State of ART review

Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19)Hydroxychloroquine: A magic bullet?

The role of medications in the pre and post prophylaxis against COVID-19

COVID and Cardiometabolic Challenges

Multidisciplinary approach to COVID-19 Cardiometabolic Complications

The evolving pandemic of COVID-19 and invasive cardiology consideration

Brief description of COVID-19 effect on approaching invasive strategies in patients with CVD

COVID-19 Cath Lab Implications

A frontline View from Italy

COVID-19 Sharing Facts, Not the Fear

Quick review on COVID-19 from an ID Perspective

Ischemic Cardiomyopathy to be Revascularized and How?

Pass the torch: Educational sessions for Interventional Cardiologists, Review of ESC 2019 CCS Guideline

How to Select Appropriate Testing?

Pass the torch: Educational sessions for Interventional Cardiologists, Review of ESC 2019 CCS Guideline

Anti-ischemic Medications

Pass the torch: Educational sessions for Interventional Cardiologists, Review of ESC 2019 CCS Guideline